Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Aktis Oncology, Inc.NASDAQ: AKTS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) of 55.28M shares in Q1 FY2026

Q1 FY2026 weighted avg shares (diluted) was 55.28M shares. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
55.28M+3.5% QoQ
Last fiscal yearDec 2025
52.52M+50.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+50.6%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
52.52M USD
Year-over-year change
+50.6%
3-year CAGR
+14.6%

Weighted Avg Shares (Diluted) vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 weighted avg shares (diluted) of 52.52M shares is the 5th highest of the 6 companies compared; the peer median is 63.26M shares.
  • Its year-over-year change of +50.6% is the highest of 6, against a peer median of +7.1%.
  • Over three fiscal years its annual growth of +14.6% compares with a peer median of +26.3%.
AKTS Competitors Peer median
Weighted Avg Shares (Diluted) for AKTS and competitors
Company Period LTM YoY 3-year CAGR
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
AKTSAktis Oncology, Inc.FY202552.52M +50.6%+14.6%
IMCRImmunocore Holdings plcLTM Mar 202650.99M -0.4%+3.3%
Peer median (excluding AKTS) 63.26M+7.1%+26.3%

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.49M6.5M
Cost of Revenue0000
Gross Profit001.49M6.5M
Gross Margin——100.0%100.0%
Research & Development14.3M25.92M40.95M67.45M
Selling, General & Admin5.11M7.68M11.31M12.6M
Operating Expenses19.76M34.79M53.54M81.18M
Depreciation & Amortization445K1.2M1.58M2.33M
EBITDA(17.48M)(27.45M)(42.41M)(61.4M)
EBITDA Margin——-2851.7%-945.1%
Operating Income(19.76M)(34.79M)(52.05M)(74.68M)
Operating Margin——-3500.3%-1149.5%
Interest Income1.65M5.38M8.1M11.01M
Interest Expense0000
Other Income / Expenses1.84M6.15M8.07M10.95M
Income Before Tax(17.93M)(28.64M)(43.98M)(63.73M)
Pre-Tax Margin——-2957.6%-980.9%
Income Tax Expense0000
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Net Margin——-2957.6%-980.9%
EPS (Basic)(0.51)(0.82)(1.26)(1.19)
EPS (Diluted)(0.51)(0.82)(1.26)(1.19)
Weighted Avg Shares34.86M34.86M34.86M52.52M
Weighted Avg Shares (Diluted)34.86M34.86M34.86M52.52M

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.